Clinical trial
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating…
NCT00352131 · ImmunoGen, Inc., Industry · Completed
Key facts
| NCT number | NCT00352131 |
|---|---|
| Title | Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors |
| Official title | A Phase I Study to Assess the Safety and Pharmacokinetics of huC242-DM4 Administered as a Single Intravenous Infusion Once Every Three Weeks to Subjects With Solid Tumors |
| Lead sponsor | ImmunoGen, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-colorectal Cancer, Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | HuC242-DM4 |
| Enrollment | 50 |
| Start date | Feb 1, 2005 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Jul 14, 2006 |
| Last update posted | Mar 17, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: